<DOC>
	<DOCNO>NCT01401192</DOCNO>
	<brief_summary>This study try evaluate predictive role thymidylate synthase expression pemetrexed/cisplatin Non-small Cell Lung Cancer ( NSCLC ) .</brief_summary>
	<brief_title>Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According Thymidylate Synthase Expression</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically confirm nonsquamous NSCLC Stage IIIb , IV recurrent NSCLC Age ≥ 18years ECOG performance status 0 1 Known TS immunohistochemical analysis data At least one measurable lesion RECIST 1.1 No previous chemotherapy therapy EGFR TKIs advance NSCLC Asymptomatic brain metastasis symptomatic brain metastasis treat local treatment operation , whole brain radiotherapy , gammaknife surgery At least 2 week later whole brain radiotherapy palliative radiotherapy Adequate renal function : estimate creatinine clearance ≥ 50mL/min Patients whose disease recur within 6 month completion adjuvant chemotherapy . Patients postobstructive pneumonia uncontrolled serious infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>thymidylate synthase</keyword>
</DOC>